Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess patients with chronic heart failure and moderate-severe ventricular dysfunction (left ventricular ejection fraction (FEVE) <40%) with nocturnal desaturation (mean Oxygen saturation (SatO2) <90% and/or Cummulative time (TC) <90% > 22 minutes) without underlying respiratory disease, oxygen treatment during hours of night rest will reduce exacerbations, improve the ability to effort, sleep quality and poor prognostic parameters of heart failure, compared to patients not receiving oxygen treatment.


Clinical Trial Description

36 patients will attend at baseline, monthly, 3-month and 6-monthly visits. BASELINE VISIT After being informed about the study and potential risks, all patients giving written informed consent, will be randomized (according to the list) receiving oxygen therapy (treatment group) and those not receiving this treatment (control group). The following information will be collected: - Demographics, pathological history, concomitant medication. - Physical examination, vital signs (pressure, heart rate, weight) - Doppler echocardiography (an echocardiography performed in the last 6 months will be accepted) - Analytical determination of biomarkers NT-proBNP and ultrasensitive troponin. - Assessment of baseline functional class by NYHA classification. - Respiratory function tests: spirometry and diffusion (will accept tests performed in the last 6 months). - Arterial blood gases. - Nocturnal respiratory polygraphy. - Exercise capacity with the 6-minute walk test (P6MM) - Evaluation of health-related quality of life with the Minnesota questionnaire - Assessment of sleep quality using the Pittsburgh questionnaire If the patient belongs to the treatment group, the intervention will begin with oxygen therapy with a static concentrator and nasal cannula during the night at home, with a minimum compliance of six hours, following the usual clinical practice. Overnight pulse oximetry at home with oxygen will be performed to confirm if the prescribed flow rate is adequate to achieve a mean SatO2 >90% and/or that the correction of the CT90. If this is not achieved, it will be repeated, modifying the oxygen flow until the target is reached. The control group will not undergo this intervention. The rest of the medical treatment will be carried out according to the usual protocol of the Heart Failure Unit. Follow up visits: Clinical follow-up will be done at one month, three months and six months after the start of the intervention in the Chronic Respiratory Pathology Unit of Pneumology. At 1 and 3 months - Analytical determination of biomarkers nt-proBNP and ultrasensitive troponin (TnThs). - Baseline functional class will be collected by New York Heart Association (NYHA) classification. - Physical examination, vital signs (blood pressure (BP), Heart rate (HR), weight). - Adverse effects and concomitant medication. At 6 months - Analytical determination of biomarkers nt-proBNP and ultrasensitive troponin (TnThs). - Baseline functional class by NYHA classification will be collected. - Physical examination, vital signs (BP, HR, weight). - Evaluation of exercise capacity will be done by means of the 6-minute walk test (PM6M). - Nocturnal pulse oximetry of control: treatment group with oxygen to evaluate the response and control group without oxygen to evaluate the evolution. - Assessment of health-related quality of life with the Minnesota questionnaire. - Sleep quality will be assessed using the Pittsburgh questionnaire. - Adverse effects and concomitant medication. In the follow-up periods (1, 3 and 6 months), the number of decompensations will be recorded: - Hospitalizations for heart failure. - Emergency care for heart failure requiring at least one dose of intravenous diuretic treatment. - Need for outpatient intravenous depletive treatment due to the presence of congestive signs. The study will be considered completed after 6 months of follow-up. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05913739
Study type Interventional
Source Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Contact Marc Bonnin Vilaplana, MD
Phone +34 972 94 02 00
Email mbonnin.girona.ics@gencat.cat
Status Recruiting
Phase N/A
Start date July 1, 2023
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT03597646 - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure N/A
Terminated NCT04065997 - Apogee International
Withdrawn NCT03675113 - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure N/A
Completed NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study Phase 4
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Completed NCT02247245 - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients. N/A
Completed NCT02268500 - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT) Phase 4
Terminated NCT01906957 - Cognition and Exercise Training N/A
Completed NCT01919918 - Muscle Afferent Feedback Effects in Patients With Heart Failure Phase 1
Not yet recruiting NCT01669395 - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial N/A
Completed NCT00984529 - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia N/A
Recruiting NCT00863421 - Sleep Disordered Breathing in Patients With Chronic Heart Failure N/A
Completed NCT02840565 - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 Phase 1
Completed NCT02441218 - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study Phase 3
Completed NCT00149409 - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure Phase 2/Phase 3
Terminated NCT05532046 - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) Phase 1
Recruiting NCT04984928 - Readmission Risk of Patients With Heart Failure.
Completed NCT02814097 - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05560737 - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I